COVID-19 Vaccine Update

The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.

On 4/18 the FDA amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. This action includes authorizing the current bivalent vaccines to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations.

What does this mean for companies? If you as the employer require employees to be vaccinated to enter the workplace, moving forward, an unvaccinated individual will receive a COVID-19 bivalent mRNA vaccine. Any individual who has received the two doses of the original vaccine is not required to receive the new COVID-19 bivalent mRNA vaccine. However they may receive the new COVID-19 bivalent mRNA vaccine if they wish.

If an employee has received only one dose of the original COVID-19 mRNA monovalent vaccine, they can obtain one dose of the COVID-19 bivalent mRNA vaccine and be deemed fully vaccinated.